Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D. Blay JY, et al. Among authors: viens p. J Clin Oncol. 2007 Mar 20;25(9):1107-13. doi: 10.1200/JCO.2006.09.0183. J Clin Oncol. 2007. PMID: 17369574 Clinical Trial.
Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study.
Guastalla JP, Pujade-Lauraine E, Weber B, Cuŕe H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Viens P, Pariso D. Guastalla JP, et al. Among authors: viens p. Ann Oncol. 1998 Jan;9(1):37-43. doi: 10.1023/a:1008211909585. Ann Oncol. 1998. PMID: 9541681 Free article. Clinical Trial.
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.
Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, Caty A, Rossi JF, Viens P, Bergerat JP, Savary J, Négrier S. Escudier B, et al. Among authors: viens p. J Clin Oncol. 1999 Jul;17(7):2039-43. doi: 10.1200/JCO.1999.17.7.2039. J Clin Oncol. 1999. PMID: 10561255 Clinical Trial.
High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?
Macquart-Moulin G, Viens P, Palangié T, Bouscary ML, Delozier T, Roché H, Janvier M, Fabbro M, Moatti JP. Macquart-Moulin G, et al. Among authors: viens p. J Clin Oncol. 2000 Feb;18(4):754-64. doi: 10.1200/JCO.2000.18.4.754. J Clin Oncol. 2000. PMID: 10673516 Clinical Trial.
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
Négrier S, Caty A, Lesimple T, Douillard JY, Escudier B, Rossi JF, Viens P, Gomez F. Négrier S, et al. Among authors: viens p. J Clin Oncol. 2000 Dec 15;18(24):4009-15. doi: 10.1200/JCO.2000.18.24.4009. J Clin Oncol. 2000. PMID: 11118461 Clinical Trial.
Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients.
Viens P, Chabannon C, Pouillard P, Janvier M, Brugger W, Blay JY, Oberling F, Capdeville R, Newman C, Méresse V, Xu ZX, Platzer E, Van der Auwera P, Maraninchi D. Viens P, et al. J Clin Oncol. 2002 Jan 1;20(1):24-36. doi: 10.1200/JCO.2002.20.1.24. J Clin Oncol. 2002. PMID: 11773150 Clinical Trial.
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
Lotz JP, Bui B, Gomez F, Théodore C, Caty A, Fizazi K, Gravis G, Delva R, Peny J, Viens P, Duclos B, De Revel T, Curé H, Gligorov J, Guillemaut S, Ségura C, Provent S, Droz JP, Culine S, Biron P; Groupe d'Etudes des Tumeurs Uro-Génitales (GETUG). Lotz JP, et al. Among authors: viens p. Ann Oncol. 2005 Mar;16(3):411-8. doi: 10.1093/annonc/mdi087. Epub 2005 Jan 19. Ann Oncol. 2005. PMID: 15659420 Free article. Clinical Trial.
435 results